Cabbacis to Present at the Noble Emerging Growth Conference on October 8, 2025

Core Insights - Cabbacis is focused on developing harm-reduction tobacco products under the iBlend™ brand, with plans to present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8-9, 2025 [1][2][3] Company Overview - Cabbacis (OTCQB: CABI) is a U.S. federally-licensed tobacco product manufacturer targeting the one billion smokers globally with its patented harm-reduction products [4][5] - The flagship product, iBlend™, combines reduced-nicotine tobacco with non-intoxicating hemp, aimed at helping users smoke or vape less and transition to less harmful alternatives [4][5] Conference Participation - CEO Joseph Pandolfino will present at the conference on October 8, 2025, at 3:30 p.m. Eastern Time, and will also hold one-on-one meetings with institutional investors on October 9, 2025 [2][3] Product Development and Clinical Trials - Recent clinical trials showed that Cabbacis cigarettes received high satisfaction ratings and significantly reduced cravings for usual brand cigarettes [5] - The company is preparing to file its first Premarket Tobacco Application (PMTA) with the FDA around January 2026 and is exploring international licensing and partnership opportunities [3][5] Intellectual Property - Cabbacis holds a global patent portfolio of 35 issued patents and various pending applications, primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods across key markets [5]